Today we get to bring you a feel good story, one of the major achievements so far in precision oncology. Three large companies—Thermo Fisher, Pfizer, and Novartis—put aside their differences to come together for patients. The patients are those who suffer from non-small cell lung cancer. In June, the FDA approved for the first time an NGS panel with multiple genes for multiple drugs that treat this kind of cancer.
Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer
www.mendelspod.com
Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.Listen on
Substack App
RSS Feed
Appears in episode
Theral Timpson
Recent Episodes
Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer